|
IN184589B
(enEXAMPLES)
*
|
1996-10-16 |
2000-09-09 |
Alza Corp |
|
|
US20020182258A1
(en)
*
|
1997-01-22 |
2002-12-05 |
Zycos Inc., A Delaware Corporation |
Microparticles for delivery of nucleic acid
|
|
US7258869B1
(en)
|
1999-02-08 |
2007-08-21 |
Alza Corporation |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
|
|
DE19940748A1
(de)
*
|
1999-08-27 |
2001-03-01 |
Hugo Seinfeld |
Arzneimittel enthaltend xenogene Oligo- oder/und Polyribonukleotide
|
|
AU2046101A
(en)
*
|
1999-11-22 |
2001-06-04 |
Universal Preservation Technologies, Inc. |
Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
|
|
US7456009B2
(en)
*
|
2000-03-07 |
2008-11-25 |
Merck & Co., Inc. |
Adenovirus formulations
|
|
JP5118798B2
(ja)
*
|
2000-03-07 |
2013-01-16 |
メルク・シャープ・エンド・ドーム・コーポレイション |
アデノウイルス製剤
|
|
US7153472B1
(en)
|
2000-11-22 |
2006-12-26 |
Quadrant Drug Delivery Limited |
Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
|
|
ATE285756T1
(de)
*
|
2001-06-28 |
2005-01-15 |
Microchips Inc |
Verfahren zum hermetischen versiegeln von mikrochip-reservoir-vorrichtungen
|
|
WO2003048665A1
(en)
|
2001-12-03 |
2003-06-12 |
Massachusetts Institute Of Technology |
Microscale lyophilization and drying methods for the stabilization of molecules
|
|
CA2476859C
(en)
*
|
2002-03-13 |
2011-09-20 |
Collagenex Pharmaceuticals, Inc. |
Water-based delivery systems
|
|
JP4436258B2
(ja)
*
|
2002-08-16 |
2010-03-24 |
マイクロチップス・インコーポレーテッド |
制御された放出デバイスおよび方法
|
|
WO2004022033A1
(en)
*
|
2002-09-04 |
2004-03-18 |
Microchips, Inc. |
Method and device for the controlled delivery of parathyroid hormone
|
|
GB2410497B
(en)
*
|
2002-09-27 |
2006-11-22 |
Powderject Res Ltd |
Nucleic acid coated particles
|
|
WO2004033034A1
(en)
|
2002-10-04 |
2004-04-22 |
Microchips, Inc. |
Medical device for neural stimulation and controlled drug delivery
|
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
|
EP2526996B1
(en)
|
2002-12-20 |
2019-09-11 |
Xeris Pharmaceuticals, Inc. |
Formulation for intracutaneous injection
|
|
AU2004229465B2
(en)
*
|
2003-04-09 |
2010-04-29 |
The United States Of America Department Of Veterans Affairs |
Compositions and methods related to production of erythropoietin
|
|
ES2359243T3
(es)
*
|
2003-04-25 |
2011-05-19 |
Boston Scientific Scimed, Inc. |
Formulación de fármaco sólida y dispositivo para el almacenamiento y la administración controlada de la misma.
|
|
US7892205B2
(en)
*
|
2003-06-06 |
2011-02-22 |
Boston Scientific Scimed, Inc. |
Device and method for delivering micronized therapeutic agents in the body
|
|
ATE482650T1
(de)
*
|
2003-11-03 |
2010-10-15 |
Microchips Inc |
Medizinprodukt zum messen von glucose
|
|
US20050267440A1
(en)
*
|
2004-06-01 |
2005-12-01 |
Herman Stephen J |
Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant
|
|
US7537590B2
(en)
*
|
2004-07-30 |
2009-05-26 |
Microchips, Inc. |
Multi-reservoir device for transdermal drug delivery and sensing
|
|
US20060029551A1
(en)
*
|
2004-08-05 |
2006-02-09 |
Kui Liu |
Stable particle formulations of erythropoietin receptor agonists
|
|
US7772182B2
(en)
*
|
2004-08-05 |
2010-08-10 |
Alza Corporation |
Stable suspension formulations of erythropoietin receptor agonists
|
|
JP5107041B2
(ja)
*
|
2004-09-01 |
2012-12-26 |
マイクロチップス・インコーポレーテッド |
レザバ内容物の制御された放出または曝露のための、マルチキャップレザバデバイス
|
|
ES2827179T3
(es)
|
2004-09-10 |
2021-05-20 |
Becton Dickinson Co |
Dispositivo de reconstitución de infusión
|
|
AU2006208131A1
(en)
|
2005-01-25 |
2006-08-03 |
Microchips, Inc. |
Control of drug release by transient modification of local microenvironments
|
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
|
EP1962586B1
(en)
*
|
2005-12-22 |
2017-07-12 |
Oakwood Laboratories L.L.C. |
Sublimable sustained release delivery system and method of making same
|
|
MX2008014870A
(es)
|
2006-05-30 |
2009-02-12 |
Intarcia Therapeutics Inc |
Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
|
|
EP3421031A1
(en)
|
2006-08-09 |
2019-01-02 |
Intarcia Therapeutics, Inc |
Osmotic delivery systems and piston assemblies
|
|
LT2134353T
(lt)
*
|
2007-03-30 |
2017-03-27 |
Xisle Pharma Ventures Trust |
Dvifazė lipidų vezikulių kompozicija ir gimdos kaklelio displazijos gydymo būdas, skiriant intravaginaliai
|
|
MX2009011123A
(es)
|
2007-04-23 |
2009-11-02 |
Intarcia Therapeutics Inc |
Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
|
|
JP5658031B2
(ja)
|
2007-06-22 |
2015-01-21 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
|
|
WO2009102467A2
(en)
|
2008-02-13 |
2009-08-20 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
WO2010056657A2
(en)
|
2008-11-16 |
2010-05-20 |
Board Of Regents, The Univesity Of Texas System |
Low viscosity highly concentrated suspensions
|
|
US9283184B2
(en)
*
|
2008-11-24 |
2016-03-15 |
Massachusetts Institute Of Technology |
Methods and compositions for localized agent delivery
|
|
NZ598686A
(en)
|
2009-09-28 |
2014-05-30 |
Intarcia Therapeutics Inc |
Rapid establishment and/or termination of substantial steady-state drug delivery
|
|
JP5837519B2
(ja)
*
|
2010-03-09 |
2015-12-24 |
ヤンセン バイオテツク,インコーポレーテツド |
非水性高濃度減粘懸濁製剤
|
|
US20110223208A1
(en)
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
|
EP2547323B1
(en)
|
2010-03-17 |
2016-01-27 |
Novaliq GmbH |
Pharmaceutical composition for treatment of increased intraocular pressure
|
|
WO2012012460A1
(en)
|
2010-07-19 |
2012-01-26 |
Xeris Pharmaceuticals, Inc. |
Stable glucagon formulations for the treatment of hypoglycemia
|
|
EP2444063A1
(en)
|
2010-10-20 |
2012-04-25 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the delivery of active ingredients
|
|
EP2462921A1
(en)
|
2010-11-11 |
2012-06-13 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the treatment of a posterior eye disease
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
CN103442695B
(zh)
|
2011-03-10 |
2016-05-04 |
Xeris药物公司 |
肠胃外注射用肽药物的稳定制剂
|
|
CN103561724B
(zh)
|
2011-05-25 |
2016-06-29 |
诺瓦利克有限责任公司 |
给药给甲的药物组合物
|
|
DK3192501T3
(da)
|
2011-05-25 |
2020-08-03 |
Novaliq Gmbh |
Topisk farmaceutisk sammensætning baseret på semifluorerede alkaner
|
|
BR112014010275A2
(pt)
|
2011-10-31 |
2017-04-18 |
Xeris Pharmaceuticals Inc |
formulações para tratamento de diabetes
|
|
DK2806886T3
(en)
|
2012-01-23 |
2017-06-06 |
Novaliq Gmbh |
STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES
|
|
US9125805B2
(en)
|
2012-06-27 |
2015-09-08 |
Xeris Pharmaceuticals, Inc. |
Stable formulations for parenteral injection of small molecule drugs
|
|
CN106511322B
(zh)
|
2012-09-12 |
2021-09-17 |
诺瓦利克有限责任公司 |
包含半氟化烷烃的混合物的组合物
|
|
ES2621226T3
(es)
|
2012-09-12 |
2017-07-03 |
Novaliq Gmbh |
Composiciones de alcanos semifluorados
|
|
WO2014110491A1
(en)
|
2013-01-11 |
2014-07-17 |
Theratrophix Llc |
Prodrugs of treprostinil
|
|
US9505737B2
(en)
|
2013-01-11 |
2016-11-29 |
Corsair Pharma, Inc. |
Treprostinil derivative compounds and methods of using same
|
|
US9018162B2
(en)
|
2013-02-06 |
2015-04-28 |
Xeris Pharmaceuticals, Inc. |
Methods for rapidly treating severe hypoglycemia
|
|
JP6387392B2
(ja)
|
2013-03-15 |
2018-09-05 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第ix因子ポリペプチド製剤
|
|
PL3024484T3
(pl)
|
2013-07-23 |
2018-11-30 |
Novaliq Gmbh |
Stabilizowane kompozycje przeciwciał
|
|
US10159646B2
(en)
|
2013-08-12 |
2018-12-25 |
Altum-Avro Pharma Partnership |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
|
US8986732B2
(en)
|
2013-08-12 |
2015-03-24 |
Helix Biopharma Corporation |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
|
IL312865B2
(en)
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
|
WO2015048498A2
(en)
|
2013-09-27 |
2015-04-02 |
Massachusetts Institute Of Technology |
Carrier-free biologically-active protein nanostructures
|
|
AU2015236340B2
(en)
*
|
2014-03-24 |
2020-02-06 |
Bioverativ Therapeutics Inc. |
Lyophilized factor IX formulations
|
|
EP3828160A1
(en)
|
2014-07-16 |
2021-06-02 |
Corsair Pharma, Inc. |
Treprostinil derivative compounds and methods of using same
|
|
US11129940B2
(en)
|
2014-08-06 |
2021-09-28 |
Xeris Pharmaceuticals, Inc. |
Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
AU2015325055B2
(en)
|
2014-10-01 |
2021-02-25 |
Eagle Biologics, Inc. |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
|
AU2016270984B2
(en)
|
2015-06-03 |
2021-02-25 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
|
US9649364B2
(en)
|
2015-09-25 |
2017-05-16 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic formulations in aprotic polar solvents
|
|
US9394227B1
(en)
|
2015-06-17 |
2016-07-19 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
|
US9643911B2
(en)
|
2015-06-17 |
2017-05-09 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
|
CN116212048A
(zh)
|
2015-08-12 |
2023-06-06 |
麻省理工学院 |
纳米颗粒的细胞表面偶联
|
|
US11590205B2
(en)
|
2015-09-25 |
2023-02-28 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
|
|
CN113662928A
(zh)
|
2015-09-30 |
2021-11-19 |
诺瓦利克有限责任公司 |
用于眼部给药的半氟化化合物
|
|
WO2017055454A1
(en)
|
2015-09-30 |
2017-04-06 |
Novaliq Gmbh |
Semifluorinated compounds and their compositions
|
|
JP7077237B2
(ja)
|
2016-05-16 |
2022-05-30 |
インターシア セラピューティクス,インコーポレイティド |
グルカゴン受容体選択的ポリペプチド及びその使用方法
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
EP3468581A1
(en)
|
2016-06-13 |
2019-04-17 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
|
ES2763121T3
(es)
|
2016-06-23 |
2020-05-27 |
Novaliq Gmbh |
Método de administración tópica
|
|
PL3515420T3
(pl)
|
2016-09-22 |
2024-04-08 |
Novaliq Gmbh |
Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek
|
|
KR20190057338A
(ko)
|
2016-09-23 |
2019-05-28 |
노바리크 게엠베하 |
시클로스포린을 포함하는 안과 조성물
|
|
MX2019008006A
(es)
|
2017-01-03 |
2019-08-29 |
Intarcia Therapeutics Inc |
Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
|
|
CA3058097C
(en)
|
2017-04-21 |
2024-01-02 |
Novaliq Gmbh |
Iodine compositions
|
|
CN110650734B
(zh)
|
2017-05-12 |
2024-11-15 |
诺瓦利克有限责任公司 |
治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
|
|
EP3624846B1
(en)
|
2017-05-16 |
2024-08-07 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan
|
|
KR102646865B1
(ko)
|
2017-06-02 |
2024-03-11 |
엑스에리스 파머수티클스, 인크. |
침전 방지 저분자 약물 제제
|
|
AU2018328209A1
(en)
|
2017-09-05 |
2020-04-23 |
Torque Therapeutics, Inc. |
Therapeutic protein compositions and methods of making and using the same
|
|
CA3076776A1
(en)
|
2017-09-27 |
2019-04-04 |
Novaliq Gmbh |
Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
|
|
US11896559B2
(en)
|
2017-10-04 |
2024-02-13 |
Novaliq Gmbh |
Opthalmic compositions comprising F6H8
|
|
CA3091308A1
(en)
|
2018-03-02 |
2019-09-06 |
Novaliq Gmbh |
Pharmaceutical compositions comprising nebivolol
|
|
EP3784246A1
(en)
|
2018-04-27 |
2021-03-03 |
Novaliq GmbH |
Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
|
|
WO2019217637A1
(en)
*
|
2018-05-09 |
2019-11-14 |
Biomatrica, Inc. |
Stabilization of proteins in biological samples
|
|
SG11202102820VA
(en)
|
2018-10-12 |
2021-04-29 |
Novaliq Gmbh |
Ophthalmic composition for treatment of dry eye disease
|
|
CN113661006A
(zh)
|
2019-02-05 |
2021-11-16 |
林迪生物科学公司 |
分离的细胞培养物组分以及用于从液体细胞培养基中分离其的方法
|
|
CN113710228A
(zh)
|
2019-02-13 |
2021-11-26 |
诺瓦利克有限责任公司 |
用于治疗眼部新生血管形成的组合物和方法
|
|
US20220409705A1
(en)
|
2019-12-06 |
2022-12-29 |
Guangzhou Bioseal Biotech Co., Ltd. |
Flowable fibrinogen thrombin paste
|
|
US20220162587A1
(en)
*
|
2020-11-20 |
2022-05-26 |
Team Medical Llc |
Rna stabilization
|
|
WO2023044455A2
(en)
*
|
2021-09-16 |
2023-03-23 |
Team Medical Llc |
Rna stabilization
|